ClinicalTrials.gg
TerminatedNCT03312387MAAX-HFUpdated Sep 3, 2019

Muscle, Essential Amino Acids, and eXercise in Heart Failure

An interventional study of Exercise and Essential Amino Acids in Heart Failure, Diastolic, sponsored by Arizona State University. Terminated at 2 sites in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2019-09-03.

Sponsored by Arizona State University · Not applicable, Interventional, and Other

Why this study was terminated
There is no longer any funding to support the study

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-13

Among 95 studies in Heart Failure, Diastolic with a site in United States — 18 open to participants now, 20 under way, none of them phase 3. Heart Failure, Diastolic · United States.

Enrollment
77th of 81
1 · median 36
Started
2017
with 3 others
No phase
40 of 95
6 open now
Registered
47th of 95
by date
Lead sponsor
2 of 95
Arizona State University

Among the 95 studies in Heart Failure, Diastolic with a site in United States, this one is the 77th largest by enrollment of the 81 interventional ones that give a count, is one of 4 that started in 2017, is one of 40 with no phase, and was the 47th registered.

Heart Failure, Diastolic

199 studies on the registry are indexed under Heart Failure, Diastolic; 44 are open to participants now.

Browse Heart Failure, Diastolic studies →

Open to participants now

18 of the 95 studies in Heart Failure, Diastolic with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 29 Heart Failure, Diastolic studies recruiting now, 21 (72%) set no upper age limit and 4 (14%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Heart Failure, Diastolic with a site in United States, or all of them as a file.
02

Study summary

Half of heart failure patients have preserved ejection fraction (HFpEF). Like patients with reduced ejection fraction (HFrEF), HFpEF patients suffer from exercise intolerance (low VO2max), which reduces physical function, quality of life, and survival. Strikingly, there is no medication proven to increase survival for HFpEF patients. Whereas exercise intolerance in HFrEF patients is the result of cardiovascular limitations, physical dysfunction in HFpEF patients is largely the result of peripheral abnormalities in skeletal muscle. Indeed, research in HFpEF patients identified that physical function and VO2peak are directly related to leg lean mass, and drugs focused on improving cardiovascular function have failed to improve VO2peak. Unfortunately, no therapy has been identified for this population that can concurrently improve cardiovascular and muscle health. The need for improved muscle therapies is reinforced by the fact that HFpEF patients are commonly older adults who are predisposed to muscle wasting. Strategic essential amino acid (EAA) ingestion has been shown to improve the adaptive response of muscle to exercise. Therefore, the investigators will determine, in HFpEF patients, the extent to which ingesting a strategic mixture of EAAs during an acute aerobic exercise training program enhances the response to this exercise strategy.

03

Conditions studied

  • Heart Failure, Diastolic
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 60+ years of age
  • Able to communicate meaningfully with the investigator and must be legally competent to provide written .
  • Diagnosed with HFpEF as per established echocardiographic criteria ( Class II-III).

Exclusion criteria

Exclusion Criteria:

  • Unstable angina, myocardial infarction in the past 4 weeks
  • Uncompensated heart failure
  • class IV symptoms, complex ventricular arrhythmias, symptomatic severe aortic stenosis, acute pulmonary embolus, acute myocarditis, untreated high-risk proliferative retinopathy, recent retinal hemorrhage, uncontrolled hypertension, baseline blood screening abnormalities
  • Medication non-compliance
  • Medical / orthopedic conditions precluding exercise
  • Exercise training (>2 weekly sessions of moderate to high intensity aerobic or resistance exercise)
  • Subjects on anti-coagulation medication will not be eligible for the muscle procedure, but are deemed eligible for study participation if \< 3.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Essential Amino Acid and Exercise

    Participants will be provided with essential amino acids during exercise training.

    Other: Exercise · Dietary Supplement: Essential Amino Acids

  • Placebo comparator
    Placebo and Exercise

    Participants will be provided with placebo supplement during exercise training.

    Other: Exercise · Dietary Supplement: Placebo

Interventions

  • OtherExercise

    Aerobic exercise performed 3/d per week during intervention

  • Dietary supplementEssential Amino Acids

    Mixture of 10g of essential amino acids ingested throughout intervention

  • Dietary supplementPlacebo

    10g of maltodextrin ingested throughout intervention

06

What researchers measure

Primary outcomes

  1. Change in VO2max

    Change in maximal Aerobic Capacity

    Time frame: Change from pre to after the 4 week intervention

Secondary outcomes

  1. Change in Flow-mediated Dilation

    Change in blood vessel function

    Time frame: Change from pre to after the 4 week intervention

  2. Change in Pulse wave velocity

    Change in pulse wave velocity

    Time frame: Change from pre to after the 4 week intervention

  3. Change in Diastolic Function

    Change in diastolic Function

    Time frame: Change from pre to after the 4 week intervention

  4. Change in Skeletal Muscle mRNA expression

    Change in skeletal Muscle mRNA expression

    Time frame: Change from pre to after the 4 week intervention

07

Study locations

2 sites
  • Arizona State University
    Phoenix, Arizona 85004, United States
  • Mayo Clinic Arizona
    Scottsdale, Arizona 85259, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Dec 2018, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2017
First posted
Oct 17, 2017
StartActual
Sep 19, 2017
Primary completionActual
Dec 31, 2018
CompletionActual
Dec 31, 2018
Last update
Sep 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03312387
Collaborators
Mayo Clinic
Responsible party
Jared Dickinson (Assistant Professor, Arizona State University) — Principal investigator
First posted
Oct 17, 2017
Start date
Sep 19, 2017
Primary completion
Dec 31, 2018
Completion
Dec 31, 2018
Last update
Sep 3, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Essential amino acid

Start the discussion